Published in JAMA Oncology · View the paper (DOI)
A retrospective cohort study suggests that stopping immunotherapy treatment at two years is a valid strategy without compromising overall survival. The researchers analyzed data from 1,091 patients and found similar overall survival probabilities between those who stopped treatment and continued it indefinitely.
Coverage from 2 institutions